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abstract
PURPOSEHuman papillomavirus (HPV) testing is being more widely used in simplified cervical cancer screening
protocols in low-resource settings. One challenge to successful implementation is themultiple visits necessary to
provide results and follow-up. mHealth strategies may reduce visit burden by providing information through text
message.
METHODS As part of a cluster-randomized trial to compare HPV testing in clinics and community health
campaigns in western Kenya, we carried out a mixed-methods study to assess women’s preferences and
experiences with different strategies to receive their results. Women could opt to receive their HPV results via text
message, cell phone call, home visit, or return clinic visit. We examined overall receipt of results, follow-up rates,
and acceptability by notification method.
RESULTS Among the 4,947 women who underwent HPV-based cervical cancer screening, 1,596 (32%) re-
ceived results via text message, 1,181 (24%) via cell phone call, 1,563 (32%) via clinic visit, and 605 (12%) via
home visit. Women opting for texts or calls were younger and had higher rates of prior cervical cancer
screening, HIV testing, and modern contraceptive use (P , .001 for all). Home visits were associated with
a significantly higher rate of treatment acquisition (45%) than texts (38%), cell phone calls (38%), and clinic
visits (23%; P, .001). In a model controlling for age, prior screening, HIV testing, and contraceptive use, clinic
visits remained significantly associated with decreased odds of treatment (adjusted odds ratio, 0.45; 95% CI,
0.29 to 0.69) compared with texts. Among treated women, there was no difference in time to treatment by
notification method.
CONCLUSION Cell phone–based results notification strategies were preferred by women with greater health-
seeking behavior; however, HPV-positive women who received results via home visit were more likely to pursue
for treatment.
J Global Oncol. © 2019 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Cervical cancer remains an important public health
issue in many low-resource countries, including
Kenya, where the human papillomavirus (HPV) vac-
cine is not widely available and effective screening
coverage is low.1,2 To address the infrastructural limi-
tations in many low-resource settings, the WHO has
developed guidelines for a simplified screen-and-treat
strategy of HPV-based testing followed by cryother-
apy for women who test positive.3 A screen-and-treat
strategy with HPV is more effective than visual
screening methods at reducing the risk of cervical
intraepithelial neoplasia and cancer, provides a simple
dichotomous test result, and allows for testing via self-
collection.3-5 These characteristics facilitate screening
outside clinic settings, potentially reaching a greater
population.
In real-world settings, however, the effectiveness of
HPV-based screening programs is decreased by the
need for multiple visits for screening, results, and
indicated follow-up.6 Despite the increasing availability
of low-cost HPV testing, there currently is no available
point-of-care HPV test, making a same-day screen-
and-treat strategy impossible. Even the most simplified
strategies require two to three visits: screening, results
notification, and, for HPV-positive women, treatment.
Notification strategies must balance the need to pro-
vide adequate information about the implications of
the results and the next steps for follow-up with the
need to minimize clinic visits for women. In addition,
results notification should be inexpensive and capable
of reaching women in remote areas.
One strategy to reduce visit burden for both providers
and patients is to provide results and follow-up
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information through a text message. Potential advantages
of this mHealth strategy over follow-up through a clinic or
home visit include cost, time, and privacy.7 Various strat-
egies employing mHealth have been successfully imple-
mented to support antenatal care and family planning in
sub-Saharan Africa; however, relatively few programs or
studies have evaluated mHealth in other reproductive
health areas, such as cervical cancer screening.8 Although
mHealth has filled gaps in health care access in certain
settings, some studies have found that mHealth interventions
might not reach women who have low health literacy and that
many women, especially in rural areas, may be dependent on
male partners for cell phone access, limiting their access to
and comfort with text-based results.9-11
We sought to evaluate an approach that included two cell
phone–based options (text messages and calls) to provide
HPV results in rural Kenya, where cervical cancer rates are
high and screening coverage is limited.1,12 Kenya has high
rates of cell phone ownership,13 and mHealth strategies
have been shown to improve postcircumcision care and
adherence to prenatal and postpartum care among HIV-
infected women.14-16 To our knowledge, little work has been
done using mobile technology in cervical cancer prevention
programs, which may have more potential for stigma or
need for confidentiality compared with maternity care. We
tested a cell phone–based results notification strategy as
part of a larger trial to evaluate implementation strategies for
HPV-based cervical cancer screening in rural western
Kenya. We examined the prevalence of cell phone own-
ership, cell phone use, and willingness to receive cervical
cancer screening results by cell phone, as well as partic-
ipant characteristics associated with each method. We also
analyzed the relationship between notification method, rate
of follow-up, and time to treatment acquisition.
METHODS
We carried out this mixed-methods study as part of a cluster-
randomized trial comparing cervical cancer screening
implementation strategies in Migori County, a rural area in
western Kenya (ClinicalTrials.gov identifier: NCT2124252).
The parent study enrolled women living in the area who
were eligible for cervical cancer screening per Kenyan
guidelines (age 25 to 65 years with an intact uterus and
cervix). Twelve communities were assigned through a one-
to-one randomization scheme to offer self-collected HPV
testing either in community health campaigns (CHCs) held
over a 2-week period, during which the entire population of
eligible women in the community was targeted for
screening (intervention arm), or in existing Kenyan gov-
ernment health facilities, where all eligible women pre-
senting for outpatient services were targeted (control arm)
throughout the 9-month study period.
HPV testing for both arms was performed using careHPV
(QIAGEN, Germantown, MD) in a study-specific laboratory
located within the Migori County Hospital. In the CHC arm,
specimens were collected and brought to the laboratory on
a daily basis. In the health facility arm, results were col-
lected and returned to the clinic on a weekly basis. Results
notification strategies and follow-up referrals were the same
in both arms. Details about the study design and main
outcomes are described in detail elsewhere.17
Notification Strategies
After enrollment, women who said they had their own cell
phone or access to a cell phone with which they felt
comfortable receiving results were offered the option of
receiving their results via text message or call (Fig 1). The
text message content was developed through focus group
discussions, piloted before study launch (Table 1), and
shown to participants at the time of screening to ensure
understanding. Text messages were sent out in the par-
ticipants’ preferred language (Kiswahili, Dhluou, or English)
using Frontline SMS software (https://www.frontlinesms.
com/), which indicated whether the message had been
sent successfully or failed to reach the participant’s cell
phone. Frontline SMS does not provide identity or
CONTEXT
Key Objective
mHealth interventions are increasingly being adopted to bridge health care gaps in low-resource settings. We sought to
understand the preferences of women in rural western Kenya around cell phone–based notification strategies for human
papillomavirus test results and the impact of their notification choice on appropriate follow-up.
Knowledge Generated
Approximately two thirds of women had access to a cell phone and felt comfortable receiving results via call or text message.
Cell phone preference was highly correlated with other health-seeking behaviors; however, women who received results by
cell phone call or text message were not more likely to access treatment.
Relevance
These findings should prompt further investigation into cell phone use patterns among women in rural areas. Strategies for
results notification and healthmessagingmust ensure options for women without access to cell phones and provide content
that is understandable and effective.
Huchko et al
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message-read confirmation. Cell phone calls were made by
trained study staff, who asked the participant to confirm
her name, date of birth, and study participation before
sharing results and follow-up information. Participants were
able to ask any questions and provided with a number to
text or call if they wanted clarification later.
Women who did not own or feel comfortable using a cell
phone were offered the option of returning to the clinic
where they were screened (for those in health facility arm)
or their nearest clinic (for those in the CHC arm) or
obtaining their results through a home visit from a com-
munity health volunteer (CHV) or a study assistant. For
HPV-positive women who did not collect their results from
the clinic within 4 weeks, follow-up via a home visit oc-
curred. Participants were analyzed within the notification
category chosen at the time of study enrollment.
The study tracked the process and success of results
notification through an electronic database generated by
Frontline SMS and paper-based logs entered into an Excel
spreadsheet for the other notification methods. In the logs,
study staff noted the screening results, notification method,
number of attempts to reach the participant, whether and
when notification was successful, and comments on why it
was not. Research assistants attempted four cell phone
calls or three home visits before determining that a par-
ticipant was unable to be reached, and results were pro-
vided to their local clinic. For participants who opted for
a clinic visit, lists of results were provided to the clinics on
a weekly basis. When the participant returned to collect her
results, CHVs at the clinic assigned to the study would
indicate that the results were received and enter the date.
For results confirmed to have been received but missing the
date of receipt, the date that results were delivered to the
clinic was used as the notification date. Paper-based data
from these sources was entered into an electronic database
approximately every 6 weeks.
Treatment
Women who tested HPV positive were referred for evalu-
ation for cryotherapy at Migori County Hospital. Before
treatment, all women underwent a visual inspection with
acetic acid to ensure that they did not have any contra-
indications to cryotherapy and did not need a more
Own or access to
cell phone
Home visit okay?Yes
No No
No
Yes
Yes
Clinic follow-up
Cell phone call
Comfortable receiving
results by cell phone
Text okay?
Understand text?
FIG 1. Strategy to determine
the optimal method to provide
results of HPV self-testing.
TABLE 1. Content of Text Messages Sent to Provide Results of HPV Testing
HPV Result HIV Negative HIV Positive
Negative [Participant name], thank you for taking the cervical cancer
screening test. Good news—your result was negative. Visit your
nearest clinic after 5 years (2021) for another test. Please call or
flash [study number] if you have questions.
[Participant name], thank you for taking the cervical cancer
screening test. Good news—your result was negative. Visit your
nearest clinic after 1 year (2017) for another test. Please call or
flash [study number] if you have questions.
Positive [Participant name], thank you for taking the cervical cancer
screening test. The results showed that you have HPV. Please
come to Migori County Hospital to talk about treatment options.
Call or flash [study number] if you have questions.
Same as HIV negative
Indeterminate [Participant name], thank you for taking the cervical cancer
screening test. Sorry that we were not able to evaluate your
sample. We would like to collect another sample from you. Call
or flash [study number] if you have questions.
Same as HIV negative
Abbreviation: HPV, human papillomavirus.
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extensive procedure, such as a loop electrosurgical exci-
sion procedure, or referral for evaluation of invasive cancer.
Treatment was provided by trained study nurses, who filled
out a treatment information sheet before initiating therapy.
These forms were collected by study staff and entered into
tablets on a daily basis and were used to ascertain whether
the participant successfully acquired treatment.
Data Analysis
Data were queried for quality and completeness, sum-
marized using descriptive statistics, and then analyzed for
bivariate relationships using SAS software (SAS Institute,
Cary, NC). Comparisons between notification groups were
performed using χ2 or Fisher’s exact tests for categorical
variables and Kruskal-Wallis test for continuous variables. A
two-sided P value of , .05 was considered significant. We
created two multivariable models using R software (version
3.3.3; https://www.r-project.org/) to better characterize the
impact of the notification methods on timely treatment
acquisition. Variables that were found to be significant in
the bivariate analysis were included in a multivariable lo-
gistic regression to examine the relationship between no-
tification type and treatment uptake among all HPV-positive
women. A linear regression model was created to examine
time to treatment among the subgroup of HPV-positive
women who accessed treatment within the study period.
For this analysis, we investigated notification success and
treatment uptake within 4 months of screening date.
Women who did not receive results or obtain treatment
within that time continued to undergo intensified tracking
by the research team; however, they were not included in
the analysis.
Ethical Approval
This study received ethical approval from the Kenya
Medical Research Institute, Duke University institutional
review board, and University of California San Francisco
Committee for Human Subjects Research. All participants
provided written consent at the time of screening.
RESULTS
Between January and September 2016, 4,947 women
underwent cervical cancer screening with self-collected
HPV tests in clinics (n = 2,046) or CHCs (n = 2,898),
and 1,047 (21%) tested HPV positive. Among the 376
HPV-positive women (36%) who accessed treatment,
337 (91%) did so within 3 months of receiving their
results.17
At the time of screening, 3,570 women (72%) reported that
they had their own cell phone or had access to one that they
felt comfortable using (Table 2). Approximately one third of
women opted to receive their results via text message (n =
1,596; 32%), and another third opted for a return clinic visit
(n = 1,563; 32%). The remaining participants were split
between cell phone call (n = 1,181; 24%) and home visit
(n = 607; 12%). Among women opting for a home visit or
return clinic visit, 136 (22%) and 658 (42%), respectively,
reported access to a cell phone. There was a significant
difference between the study arms in access to cell phones
(CHC arm, 77% v health facility arm, 65%; P , .001)
and in choice of notification method. In the CHC arm, a
majority of women preferred to receive their results by text
(34%) or cell phone call (36%). In the health facility arm,
most women preferred to return to the health facility to
obtain their self-test results (62%).
Text messaging was the most successful route for notifi-
cation of results, with 100% confirmation that the texts were
received (Table 3). This was followed by home visit (98%),
cell phone call (83%), and return clinic visit (62%). Among
84 HPV-positive women who did not return to the clinic for
their results, 11 received their results through a home visit.
Route of notification was significantly associated with
treatment access. Almost half of women who received their
results at a home visit (45%) accessed treatment, com-
pared with women who opted for text (38%), cell phone call
(38%), or clinic visit (23%; P, .001). In the subset of 196
women who opted for a return clinic visit and actually re-
ceived their results, 62 (32%) successfully accessed
treatment. On multivariable analysis controlling for prior
screening, HIV testing, and contraceptive use, only clinic
visits remained significantly associated with decreased
odds of treatment (adjusted odds ratio, 0.45; 95% CI,
0.29 to 0.70) and time to treatment compared with text
messaging.
There was a statistically significant difference in time be-
tween screening and receipt of results by notification
method, with text messaging being the most efficient
strategy (17 days; IQR, 12-27). The same pattern was
also seen in time between screening and treatment.
HPV-positive women who received their results through
a return clinic visit had the longest median delay between
screening, notification, and treatment at 49 days (IQR, 24-
94 days), compared with 9 days (IQR, 5-28 days) for cell
phone calls, 15.5 days (IQR, 10-38.5 days) for texts, and
15 days (IQR, 6-29 days) for home visits (P, .001). There
were significant differences in median time between
screening and notification by study arm (CHC arm, 20 days
v health facility arm, 23 days; P = .004) and between
notification and treatment access among HPV-positive
women (CHC arm, 13 days v health facility arm, 25
days; P , .001). These differences went away when
controlling for notification preferences.
DISCUSSION
This study showed that women were able to receive and act
upon HPV results provided to them by cell phone, either
through a call or text message. Despite the fact that text
messaging was the most efficient way to receive results, it
was not associated with higher rates of treatment access.
Overall, returning to the clinic to obtain results was an
inefficient and ineffective strategy, requiring a second visit
Huchko et al
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for participants, reaching fewer than two thirds of women
tested and resulting in lower treatment uptake for those who
needed it. Given the overall low rate of treatment acqui-
sition, notification strategies need to be addressed, along
with other significant treatment barriers, such as distance
to treatment center, transportation costs, and health un-
derstanding, to make this two-step screen-and-treat pro-
gram more effective.
Although mHealth strategies are promising ways to address
many of the gaps in service delivery in rural areas, efficacy
is limited by lack of cell phone access in some areas. In this
study, 72% of women had access to a cell phone they were
comfortable using to receive results. This rate is also lower
than what has been seen in other studies and reports.18,19
This difference may result from the rural and impoverished
study setting, lower cell phone ownership among women
compared with men, or unwillingness to receive potentially
sensitive health information by cell phone.20 We also found
that women who reported access to cell phones had other
characteristics that suggested health-seeking behavior,
such as family planning use and prior HIV testing. The low
rates of cell phone access among women who opted for
home visits or clinic pick-up suggests that one of the driving
factors in choosing a cell phone–based method was simply
owning or having access to a cell phone. However, the fact
that more than 40% of the women opting to collect their
TABLE 2. Clinical and Demographic Characteristics of Women Undergoing HPV Screening by Notification Type
Characteristic
No. (%)
P
Notification Option
Cell Phone Call
(n = 1,181)
Text
(n = 1,596)
Home Visit
(n = 607)
Clinic Visit
(n = 1,563)
Age, years , .001
Mean 37.4 36.0 40.4 38.2
SD 10.3 9.2 12.5 10.9
Access to cell phone 1,181 (100) 1,596 (100) 136 (22) 658 (42) , .001
Prior screening for cervical cancer
Yes 151 (12.8) 234 (14.7) 50 (12.8) 140 (9.0) , .001
No 1,030 (87.2) 1,361 (85.3) 555 (91.7) 1,423 (91.0)
Prior HIV testing
Yes 1,158 (98.0) 1,574 (98.7) 575 (95.0) 1,527 (97.7) , .001
No 23 (2.0) 21 (1.3) 30 (5.0) 36 (2.3)
Prior HIV testing result (n = 4,834) , .001
Negative 805 (69.5) 1,134 (72.0) 407 (70.8) 1,010 (66.2)
Positive 351 (30.3) 440 (28.0) 165 (28.7) 515 (33.7)
Do not know 2 (0.2) 0 3 (0.5) 2 (0.1)
Family planning use , .001
Yes 493 (41.7) 752 (57.2) 186 (30.7) 628 (40.2)
No 688 (58.3) 843 (52.8) 419 (69.3) 935 (59.8)
Family planning type (n = 2,059) .001
Injectable 212 (43.0) 310 (41.2) 99 (53.2) 299 (47.6)
Implant 177 (35.9) 301 (40.0) 58 (31.2) 237(37.7)
Female sterilization 53 (10.8) 57 (7.9) 9 (4.8) 21 (3.3)
Intrauterine device 22 (4.5) 28 (3.7) 8 (4.3) 31 (5.0)
Pills 18 (3.6) 28 (3.7) 7 (3.8) 23 (3.7)
Male condom 8 (1.6) 19 (2.5) 5 (2.7) 9 (1.4)
Other 3 (0.6) 9 (1.2) 0 8 (1.3)
HPV results , .001
Positive 346 (29.3) 179 (11.2) 249 (41.2) 269 (17.2)
Negative 835 (70.7) 1,415 (88.7) 356 (58.8) 1,294 (82.8)
Indeterminate 0 1 (0.1) 0 0
Abbreviations: HPV, human papillomavirus; SD, standard deviation.
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results at the clinic had a cell phone suggests acceptability,
privacy, and possibly literacy were barriers.
The difference in choice of notification method had real
clinical consequences in this study. Opting to return to the
clinic for results was the least successful strategy, resulting
in a low proportion of women successfully receiving results
(62%) and an even lower proportion accessing treatment
(23%). Although text messaging and cell phone calls were
the most efficient notification methods, there were lower
rates of treatment acquisition in these groups than among
women who received their results via home visit. The lower
rates of cell phone ownership or access in the home visit
group would potentially suggest more difficulty in navigating
treatment, so it seems that the opportunity to answer
questions, along with the time, personal counseling, and
encouragement for follow-up inherent in a home visit, was
a key factor in encouraging treatment access. In addition,
home visits were carried out by CHVs from the participants’
communities, likely people with whom they had a pre-
existing relationship and whom they could possibly trust
in their health care advice. An optimal notification strategy
would combine the health information and support of
a one-on-one visit from a reliable source with the efficiency
and privacy of the cell phone–based notification strategies.
This may be successful in the form of enhanced scripts for
cell phone calls, increased face-to-face time with CHVs at
the time of screening, or improvement in counseling ma-
terials provided to patients after testing.
This study was unique in that it used a robust design to
compare implementation processes and strategies for HPV
testing. This allowed us to look at the factors that made
women choose their notification strategy, whereas a ran-
domized trial of notification strategies would have, by ne-
cessity, eliminated a large number of the participants who
could not or would not choose a cell phone–based notifi-
cation method. Because these are often the most hard-to-
reach women, we felt that a study design that eliminated
them would not address the overall study question of how to
increase access to effective screening. However, given the
chosen study design, we do not want to overstate the as-
sociation betweenmethod of results notification and access
of treatment, given the myriad confounding factors that
contribute to the selection of that method.
An additional limitation is the lack of specific information on
notification via either text message or clinic visit. Although
text message receipt was confirmed, there was no way to
ensure that the participant herself had read the message.
Regarding clinic pick-up, missing data entry for the dates
on which the results were collected from clinic led us to use
the date on which results were provided to the clinic as the
notification date. This was the most conservative strategy,
because it underestimated the time to notification, biasing
a comparison with other methods (which all had faster
turnaround) toward the null hypothesis of no difference. We
are therefore confident that the observed statistical dif-
ferences are real, even if the actual magnitude of the dif-
ference is greater.
Cell phones and other mHealth interventions have the
potential to bridge infrastructural and informational gaps in
many settings. Among women in low-resource settings,
these strategies may increase access to health information
that had previously been controlled by male partners or had
been inaccessible because of distance from health facilities
or poor translation into understandable messaging. This
study shows that women in a rural area of western Kenya
with limited health care infrastructure were willing and able
to use cell phones to receive the results from an HPV testing
campaign. This may be an important addition to an HPV-
based screening strategy to reduce the additional visit for
results. This also opens the door to the possibility of the
wider use of cell phones in cervical cancer prevention
strategies and other reproductive health interventions. Al-
though text messaging allows for more automation and
efficiency, there are advantages to personalized messag-
ing. The results also made it clear that there are other
barriers to accessing the treatment necessary to make
cervical cancer prevention programs effective and that
cell phone coverage and comfort are not universal.
mHealth is a promising strategy; however, any next steps
must take into account the multiple behavioral and logis-
tical barriers that ultimately affect a woman’s ability to
access health care.
AFFILIATIONS
1Duke University, Durham, NC
2Kenya Medical Research Institute, Nairobi, Kenya
3University of California San Francisco, San Francisco, CA
4Aga Kahn University, Nairobi, Kenya
The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of
Health.
CORRESPONDING AUTHOR
Megan J. Huchko, MPH, MD, 310 Trent Drive, Room 204, Box 90519,
Durham, NC 27708; e-mail: megan.huchko@duke.edu.
PRIOR PRESENTATION
Presented orally at the 32nd International Papillomavirus Meeting,
Sydney, NSW, Australia, October 2-6, 2018.
SUPPORT
Supported by National Cancer Institute Award No. R01-CA188428.
AUTHOR CONTRIBUTIONS
Conception and design: Megan J. Huchko, Cinthia Blat, Elizabeth A.
Bukusi
Use of Cell Phones to Provide HPV Results in Western Kenya
Journal of Global Oncology 7
Downloaded from ascopubs.org by 197.136.150.10 on October 26, 2020 from 197.136.150.010
Copyright © 2020 American Society of Clinical Oncology. See https://ascopubs.org/go/authors/open-access for reuse terms.
Financial support: Megan J. Huchko
Administrative support: Sandra Oketch, Elizabeth A. Bukusi
Provision of study material or patients: Sandra Oketch
Collection and assembly of data: Megan J. Huchko, Ibrahim Saduma,
Sandra Oketch
Data analysis and interpretation: All authors
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by authors of
this manuscript. All relationships are considered compensated.
Relationships are self-held unless noted. I = Immediate Family Member,
Inst =My Institution. Relationshipsmay not relate to the subject matter of
this manuscript. For more information about ASCO’s conflict of interest
policy, please refer to www.asco.org/rwc or ascopubs.org/jgo/site/misc/
authors.html.
No potential conflicts of interest were reported.
ACKNOWLEDGMENT
We thank Easter Olwanda and Job Andrews for their coordination of study
and data activities and Katelyn Bryant-Comstock and Yujung Choi for
assistance with tables and editing of this manuscript.
REFERENCES
1. Bruni L, Barrionuevo-Rosas L, Albero G, et al: Human Papillomavirus and Related Diseases Report: Kenya. https://hpvcentre.net/statistics/reports/KEN.pdf
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